Development of a new vaccine against human coronavirus causing severe pneumonia
| Project/Area Number |
16K09951
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Infectious disease medicine
|
|---|
| Research Institution | National Institute of Infectious Diseases |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2016-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | ワクチン / 重症肺炎 / コロナウイルス / 感染症防御 / 新規ワクチン / ヒトコロナウイルス |
|---|
| Outline of Final Research Achievements |
The spike (S) protein of coronavirus is a candidate vaccine target for blocking coronavirus infection. However, some animal studies have suggested that inadequate immunization against SARS‐CoV induces a lung eosinophilic immunopathology upon infection. The present study evaluated two kinds of vaccine adjuvants for use with recombinant S protein: gold nanoparticles (AuNPs) and Toll like receptor (TLR) agonists. The AuNP‐adjuvanted protein induced a strong IgG response but failed to improve vaccine efficacy or to reduce eosinophilic infiltration because of highly allergic inflammatory responses. On the other hand, the TLR agonist‐adjuvanted vaccine induced highly protective antibodies without eosinophilic infiltrations. The findings of this study will support the development of vaccines against severe pneumonia‐associated coronaviruses.
|
| Academic Significance and Societal Importance of the Research Achievements |
SARSはアジアを中心に2003年に大流行した重症呼吸器感染症で、現在は終息しているが再興の可能性がある。そしてMERSは2012年に中東で発見された新規のヒトコロナウイルスであるMERS-CoVが原因で重症肺炎を起こす。現在も患者数は増加し、2015年の春には隣国の韓国で、病院内のアウトブレイクが起こり、一大ニュースとなった。これらの重症呼吸器感染症に対して、ハイリスク者および医療従事者へのワクチン接種が流行防止措置として上げられるが、候補となるワクチンは未だにない。本研究で得られた結果は、重症肺炎を起こすヒトコロナウイルスに対する新規ワクチンの開発において、それをサポートするものである。
|
Report
(5 results)
Research Products
(9 results)
-
[Journal Article] Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs.2019
Author(s)
Hanako Sekimukai, Naoko Iwata-Yoshikawa, Shuetsu Fukushi, Hideki Tani, Michiyo Kataoka, Tadaki Suzuki, Hideki Hasegawa, Kenichi Niikura, Katsuhiko Arai, Noriyo Nagata.
-
Journal Title
Microbiology and Immunology
Volume: 64
Issue: 1
Pages: 33-51
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Acute respiratory infection in human dipeptidyl peptidase 4-transgenic mice infected with Middle East respiratory syndrome coronavirus2019
Author(s)
Naoko Iwata-Yoshikawa, Tadashi Okamura, Yukiko Shimizu, Osamu Kotani, Hironori Sato, Hanako Sekimukai, Shuetsu Fukushi, Tadaki Suzuki, Yuko Sato, Makoto Takeda, Masato Tashiro, Hideki Hasegawa, Noriyo Nagata.
-
Journal Title
J Virol.
Volume: 93
Issue: 6
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
